https://doi.org/10.65770/FPYD6165
ABSTRACT
Sickle Cell Disease (SCD) is a monogenic hemoglobinopathy arising from a single point mutation in the β-globin gene (Glu6Val), which replaces a polar glutamic acid residue with a hydrophobic valine in the β-chain of hemoglobin. Although structurally subtle, this substitution fundamentally alters intermolecular interactions within deoxygenated hemoglobin, promoting hydrophobic association, nucleation, and polymerization of hemoglobin S (HbS). The resulting supramolecular fiber formation drives erythrocyte deformation, membrane fragility, hemolysis, vaso-occlusion, and progressive tissue and organ injury. From a chemical standpoint, SCD represents a paradigmatic example of how atomic-scale perturbations propagate across hierarchical levels, from molecular structure and intermolecular interactions to cellular dysfunction, tissue injury, and systemic disease. In this review, we synthesize evidence from more than 160 peer-reviewed studies to examine the chemistry of HbS polymerization, intermolecular thermodynamics, reaction kinetics, redox imbalance, membrane oxidative damage, and the biophysical determinants of sickling. Particular emphasis is placed on the physical chemistry governing nucleation dynamics, allosteric modulation of oxygen affinity, and reactive oxygen species (ROS) generation within sickled erythrocytes. The review further connects these molecular and cellular processes with the pathological consequences observed at the tissue and organ levels, including microvascular injury, ischemia–reperfusion damage, chronic inflammation, fibrosis, and characteristic structural alterations in organs affected by SCD. This pathology-centered perspective provides a bridge between molecular mechanisms and the morphological manifestations of chronic sickle cell injury. We also evaluate emerging chemical therapeutics, including allosteric hemoglobin modifiers, antisickling agents, redox modulators, and fetal hemoglobin inducers, through the lens of structure–activity relationships and mechanistic biochemistry. Analytical and computational approaches, including spectroscopy, crystallography, molecular docking, molecular dynamics simulations, and histopathological assessment, are discussed as complementary platforms for linki ng molecular events with cellular and tissue-level phenotypes and for guiding rational therapeutic development. By integrating molecular chemistry, biophysical dynamics, tissue pathology, and translational pharmacology, this review provides a chemist-centered framework that reframes SCD not merely as a genetic disorder, but as a disorder in which altered molecular interactions propagate through cellular, tissue, and organ systems to produce pathological remodeling, thereby highlighting new avenues for chemically informed therapeutic innovation.
References
- Lettre G. Blocking HbS Polymerization in SCD. Cell. 2020 Mar 5;180(5):819. doi: 10.1016/j.cell.2020.01.019. PMID: 32142671.
- Suhail M. Biophysical chemistry behind sickle cell anemia and the mechanism of voxelotor action. Sci Rep. 2024 Jan 22;14(1):1861. doi: 10.1038/s41598-024-52476-8. PMID: 38253605; PMCID: PMC10803371.
- Nicola J Rutherford-Parker, Sean T Campbell, Jennifer M Colby, Zahra Shajani-Yi, Voxelotor Treatment Interferes With Quantitative and Qualitative Hemoglobin Variant Analysis in Multiple Sickle Cell Disease Genotypes, American Journal of Clinical Pathology, Volume 154, Issue 5, November 2020, Pages 627–634, https://doi.org/10.1093/ajcp/aqaa067
- Vichinsky E., et al. Voxelotor in SCD improves hemoglobin and reduces hemolysis: phase 3 results. New Engl. J. Med. https://doi.org/10.1056/NEJMoa1903212
- Steinberg MH, Sebastiani P. Genetic modifiers of sickle cell disease. American journal of hematology. 2012 Aug;87(8):795-803. https://doi.org/10.1002/ajh.23232
- Gopalsamy A, Aulabaugh AE, Barakat A, Beaumont KC, Cabral S, Canterbury DP, Casimiro-Garcia A, Chang JS, Chen MZ, Choi C, Dow RL. PF-07059013: a noncovalent modulator of hemoglobin for treatment of sickle cell disease. Journal of Medicinal Chemistry. 2020 Dec 24;64(1):326-42. https://doi.org/10.1021/acs.jmedchem.0c01518
- Wang Q, Zennadi R. The Role of RBC Oxidative Stress in Sickle Cell Disease: From the Molecular Basis to Pathologic Implications. Antioxidants (Basel). 2021 Oct 13;10(10):1608. doi: 10.3390/antiox10101608. PMID: 34679742; PMCID: PMC8533084.
- Nolfi-Donegan D, Pradhan-Sundd T, Pritchard KA Jr, Hillery CA. Redox Signaling in Sickle Cell Disease. Curr Opin Physiol. 2019 Jun;9:26-33. doi: 10.1016/j.cophys.2019.04.022. Epub 2019 May 2. PMID: 31240269; PMCID: PMC6592428.
- Alayash AI. Oxidative pathways in the sickle cell and beyond. Blood Cells Mol Dis. 2018 May;70:78-86. doi: 10.1016/j.bcmd.2017.05.009. Epub 2017 May 20. PMID: 28554826; PMCID: PMC5696113.
- Sundd P, Gladwin MT, Novelli EM. Pathophysiology of Sickle Cell Disease. Annu Rev Pathol. 2019 Jan 24;14:263-292. doi: 10.1146/annurev-pathmechdis-012418-012838. Epub 2018 Oct 17. PMID: 30332562; PMCID: PMC7053558.
- Eaton WA, Hofrichter J. Sickle cell hemoglobin polymerization. Adv Protein Chem. 1990;40:63-279. doi: 10.1016/s0065-3233(08)60287-9. PMID: 2195851.
- Vekilov PG. Sickle-cell haemoglobin polymerization: is it the primary pathogenic event of sickle-cell anaemia? Br J Haematol. 2007 Oct;139(2):173-84. doi: 10.1111/j.1365-2141.2007.06794.x. PMID: 17897293.
- Makhijani VB, Cokelet GR. In vivo polymerization of sickle-cell hemoglobin: a theoretical study. Blood Cells. 1994;20(1):169-83; discussion 184-90. PMID: 7994059.
- Hofrichter J. Kinetics of sickle hemoglobin polymerization. III. Nucleation rates determined from stochastic fluctuations in polymerization progress curves. J Mol Biol. 1986 Jun 5;189(3):553-71. doi: 10.1016/0022-2836(86)90324-4. PMID: 3783684.
- Breedlove SM. Hormonal control of the anatomical specificity of motoneuron-to-muscle innervation in rats. Science. 1985 Mar 15;227(4692):1357-9. doi: 10.1126/science.3975621. PMID: 3975621.
- Briehl RW, Nikolopoulou P. Kinetics of hemoglobin S polymerization and gelation under shear: I. Shape of the viscosity progress curve and dependence of delay time and reaction rate on shear rate and temperature. Blood. 1993 May 1;81(9):2420-8. PMID: 8481521.
- Nagamani Vunnam, Scott Hansen, Dillon C. Williams, MaryJane Olivia Been, Chih Hung Lo, Anil K. Pandey, Carolyn N. Paulson, John A. Rohde, David D. Thomas, Jonathan N. Sachs, and David K. Wood Biomacromolecules2022 23 (9), 3822-3830. DOI:10.1021/acs.biomac.2c00671
- Ferrone FA. Polymerization and sickle cell disease: a molecular view. Microcirculation. 2004 Mar;11(2):115-28. doi: 10.1080/10739680490278312. PMID: 15280087.
- Pagare PP, Rastegar A, Abdulmalik O, Omar AM, Zhang Y, Fleischman A, Safo MK. Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property. Expert Opin Ther Pat. 2022 Feb;32(2):115-130. doi: 10.1080/13543776.2022.1994945. Epub 2021 Nov 1. PMID: 34657559; PMCID: PMC8881396.
- Suhail M. Biophysical chemistry behind sickle cell anemia and the mechanism of voxelotor action. Sci Rep. 2024 Jan 22;14(1):1861. doi: 10.1038/s41598-024-52476-8. PMID: 38253605; PMCID: PMC10803371.
- Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995 May 18;332(20):1317-22. doi: 10.1056/NEJM199505183322001. PMID: 7715639.
- Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP; Investigators of the Phase 3 Trial of l-Glutamine in Sickle Cell Disease. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. N Engl J Med. 2018 Jul 19;379(3):226-235. doi: 10.1056/NEJMoa1715971. PMID: 30021096.
- Taylor CM, Kasztan M, Sedaka R, Molina PA, Dunaway LS, Pollock JS, Pollock DM. Hydroxyurea improves nitric oxide bioavailability in humanized sickle cell mice. Am J Physiol Regul Integr Comp Physiol. 2021 May 1;320(5):R630-R640. doi: 10.1152/ajpregu.00205.2020. Epub 2021 Feb 24. PMID: 33624556; PMCID: PMC8163606.
- Gladwin MT, Schechter AN. Nitric oxide therapy in sickle cell disease. Semin Hematol. 2001 Oct;38(4):333-42. doi: 10.1016/s0037-1963(01)90027-7. PMID: 11605168.
- Mbadiko, C.M., Ngbolua, KtN., Bongo, G.N. et al.In vitro evaluation of curcumin’s antisickling activity and in silico analysis of curcuminoids and their ADMET properties. Chem. 2, 113 (2025). https://doi.org/10.1007/s44371-025-00171-6
- Nolfi-Donegan D, Pradhan-Sundd T, Pritchard KA Jr, Hillery CA. Redox Signaling in Sickle Cell Disease. Curr Opin Physiol. 2019 Jun;9:26-33. doi: 10.1016/j.cophys.2019.04.022. Epub 2019 May 2. PMID: 31240269; PMCID: PMC6592428.
- Strader, M.B., Jana, S., Meng, F. et al.Post-translational modification as a response to cellular stress induced by hemoglobin oxidation in sickle cell disease. Sci Rep 10, 14218 (2020). https://doi.org/10.1038/s41598-020-71096-6
- Vona, R.; Sposi, N.M.; Mattia, L.; Gambardella, L.; Straface, E.; Pietraforte, D. Sickle Cell Disease: Role of Oxidative Stress and Antioxidant Therapy. Antioxidants2021, 10, 296. https://doi.org/10.3390/antiox10020296
Download all article in PDF
